Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott : Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC

09/02/2021 | 09:31am EDT

ABBOTT PARK, Ill., Sept. 2, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots. Walk Vascular's peripheral thrombectomy systems will be incorporated into Abbott's existing endovascular product portfolio. Financial terms were not disclosed.

"The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott's ability to provide one-of-a-kind endovascular therapy solutions to improve patient care," said Julie Tyler, senior vice president of Abbott's vascular business. "Walk Vascular's technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care."

Walk Vascular's JETi Peripheral Thrombectomy System and next-generation JETi AIO (All In One) Peripheral Thrombectomy System are unique aspiration systems for the removal of intravascular clots, known as thrombus, that can reduce blood flow and lead to serious complications for patients. The innovative JETi systems are designed to break-up and remove clots from the peripheral vascular system while reducing the risk of dislodged clots. The systems are backed by real-world clinical experiences, and Walk is currently enrolling up to 250 patients in the United States and Europe in the JETi Registry.

Both the JETi Peripheral Thrombectomy Systems have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, as well as CE Mark in Europe and approvals in other countries.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

 

Cision
View original content:https://www.prnewswire.com/news-releases/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc-301368214.html

SOURCE Abbott


ę PRNewswire 2021
All news about ABBOTT LABORATORIES
10/15ABBOTT LABORATORIES : Recalls Two COVID-19 Lab Kits After False Results
MT
10/14Abbott Labs unit recalling two COVID-19 lab test kits - FDA
RE
10/14Abbott Labs unit recalling two COVID-19 test kits - FDA
RE
10/14ABBOTT LABORATORIES : Redburn Partners Starts Abbott Laboratories at Neutral
MT
10/14ABBOTT LABORATORIES : Ex-dividend day for
FA
10/11Health Care Stocks Sliding in Late Monday Trading
MT
10/11Health Care Stocks Drifting Monday as Biotechs Climb
MT
10/01ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
09/30ABBOTT : Commits to Reducing Malnutrition Globally with Launch of Abbott : Center for Maln..
PR
09/30Abbott Laboratories Launches Effort to Reduce Worldwide Malnutrition
DJ
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations